These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 2112057

  • 1. High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.
    Sanchiz F, Milla A.
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S91-2. PubMed ID: 2112057
    [Abstract] [Full Text] [Related]

  • 2. Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
    Steger GG, Dittrich C, Schlappack O, Mader R, Herold C, Brade WP, Keller A, Moser K.
    J Cancer Res Clin Oncol; 1988; 114(6):602-4. PubMed ID: 3144554
    [Abstract] [Full Text] [Related]

  • 3. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.
    Paridaens R, Focan C, Michel J, Piccart M, Salamon E, Beauduin M, Closon MT, Tueni E, Vindevoghel A, Majois F.
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S63-5. PubMed ID: 2112055
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial with high-dose ifosfamide and mesna given in a 24-h infusion for advanced GI tract cancer.
    Focan C, Boossy J, Focan-Henrard D, Reginster M, Claessens JJ.
    Cancer Chemother Pharmacol; 1989; 23(3):192-3. PubMed ID: 2493996
    [Abstract] [Full Text] [Related]

  • 5. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
    Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD.
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
    [Abstract] [Full Text] [Related]

  • 6. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
    Stuart-Harris RC, Harper PG, Parsons CA, Kaye SB, Mooney CA, Gowing NF, Wiltshaw E.
    Cancer Chemother Pharmacol; 1983 Feb; 11(2):69-72. PubMed ID: 6414732
    [Abstract] [Full Text] [Related]

  • 7. Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.
    Cervellino JC, Araujo CE, Pirisi C, Sanchez O, Brosto M, Rossi R.
    Cancer Chemother Pharmacol; 1990 Feb; 26 Suppl():S1-3. PubMed ID: 2112052
    [Abstract] [Full Text] [Related]

  • 8. A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
    Cantwell BM, Carmichael J, Ghani S, Harris AL.
    Cancer Chemother Pharmacol; 1988 Feb; 21(1):49-52. PubMed ID: 3124971
    [Abstract] [Full Text] [Related]

  • 9. Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma.
    Turrill M, Spicer DV, Kelley AS, Herman RL, Russell CA, Muggia FM.
    Cancer Invest; 1995 Feb; 13(2):160-4. PubMed ID: 7874569
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. High-dose ifosfamide with mesna uroprotection: a phase I study.
    Elias AD, Eder JP, Shea T, Begg CB, Frei E, Antman KH.
    J Clin Oncol; 1990 Jan; 8(1):170-8. PubMed ID: 2104923
    [Abstract] [Full Text] [Related]

  • 12. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
    Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD.
    Cancer Chemother Pharmacol; 1990 Jan; 26 Suppl():S55-8. PubMed ID: 2112054
    [Abstract] [Full Text] [Related]

  • 13. Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer.
    Manegold C, Worst P, Bickel J, Schmid H, Drings P, Kaufmann M.
    Cancer Chemother Pharmacol; 1990 Jan; 26 Suppl():S87-90. PubMed ID: 2112056
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
    Scheulen ME, Niederle N, Bremer K, Schütte J, Seeber S.
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():93-101. PubMed ID: 6414700
    [Abstract] [Full Text] [Related]

  • 15. Severe renal failure following high-dose ifosfamide and mesna.
    Willemse PH, de Jong PE, Elema JD, Mulder NH.
    Cancer Chemother Pharmacol; 1989 Sep; 23(5):329-30. PubMed ID: 2495864
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).
    Sutton GP, Blessing JA, Rosenshein N, Photopulos G, DiSaia PJ.
    Am J Obstet Gynecol; 1989 Aug; 161(2):309-12. PubMed ID: 2548382
    [Abstract] [Full Text] [Related]

  • 17. Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results.
    Willemse PH, vd Burg ME, vd Gaast A, Neijt JP, ten Bokkel Huinink WW, Aalders JG, de Vries EG.
    Cancer Chemother Pharmacol; 1990 Aug; 26 Suppl():S51-4. PubMed ID: 2112053
    [Abstract] [Full Text] [Related]

  • 18. Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study.
    Cervellino JC, Araujo CE, Pirisi C, Francia A, Cerruti R.
    Oncology; 1991 Aug; 48(2):89-92. PubMed ID: 1900124
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
    Ingle JN, Krook JE, Mailliard JA, Hartmann LC, Wieand HS.
    Am J Clin Oncol; 1995 Dec; 18(6):498-501. PubMed ID: 8526193
    [Abstract] [Full Text] [Related]

  • 20. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
    Jürgens H, Exner U, Kühl J, Ritter J, Treuner J, Weinel P, Winkler K, Göbel U.
    Cancer Chemother Pharmacol; 1989 Dec; 24 Suppl 1():S40-4. PubMed ID: 2503258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.